Autolus Therapeutics stock
AUTLNASDAQAutolus Therapeutics plc, HealthcareISIN US05280R1005
31Score 31 out of 100, Weak
Price and trend
37 / 100
Price history
−13% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 28% below it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 24).
The price is 53% below its 52-week high. Largest decline in 8 years: 98% (November 2018 to April 2025).
Chart figures for advanced users
- SMA 50$1.72
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$1.66
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)24
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$1.19
- The lowest closing price of the last twelve months.
- Resistance$2.54
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Autolus Therapeutics plc belongs to the Biotechnology industry (United Kingdom) and, with a market value of $316.73M, is number 284 of 296 companies in its industry on MEQIRI.
- This is an American depositary receipt (ADR).
- In fiscal 2025 it reported revenue of $75.56M (up 646.7% year on year) and a loss of $288.2M.
Show more
- MEQIRI Score 31 out of 100 (Weak): rank 678 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 113.2% a year since 2020, Biotechnology median 19.7%.Growth 70
- More cash than debtCash $248.38M, financial debt $147.87M.
Weaknesses
- DilutionShare count up 416% since 2020.Capital allocation 18
- High debtDebt 5.4 times equity (latest quarter), Biotechnology median 0.09.Stability 26
- Loss-makingLoss of $256M over the last 12 months.Fundamentals 17
Its standout strength is growth, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 32 to 31.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Sep 2026, revenue rose 94.6% on the same quarter a year earlier. Revenue has grown strongly since 2014, at around 95% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross −28%, operating −372%, net −381%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 10 Mar 2027in 118 days
- Last reported
- 10 Nov 2026in line with expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −0.78+0.4%
- Revenue
- $149.4M0.0%
- Earnings per share
- −0.63+0.6%
- Revenue
- $199.96M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +2.4%2026 net product revenue guidance raised to $140 million to $150 million (previously $120 million to $135 million).
“When we look at the net revenue projection that we had for the year that was originally set at $120 million to $135 million, we're now at a point where we can actually increase our guidance to $140 million to $150 million for the full year.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 11 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $15,682 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Piccina CintiaSale
2 Sept 2026, U.S. CCO & Country Gen Manager
- Shares
- 6,713
- Price
- $2.34
- Value
- $15,682
Shares and prices per ordinary share as filed with the SEC, not per depositary receipt.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Autolus Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 31
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- AgomAb TherapeuticsAGMB $344.24M30
- Faeth TherapeuticsFTH $344.15M35
- Atea PharmaceuticalsAVIR $338.46M35
- Enanta PharmaceuticalsENTA $337.85M28
- OcugenOCGN $325.87M36
- Turn TherapeuticsTTRX $320.99M45
- MapLight TherapeuticsMPLT $318.78M33
- Vicore Pharma HoldingVICO.ST $318.18M38
ETFs that hold Autolus Therapeutics
Held by 1 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.02% | 0.35% | €1.21B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2019)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.